Richard James Gilbertson: Influence Statistics

Richard James Gilbertson

Richard James Gilbertson

Department of Oncology, Cancer Research UK Cambridge Institute, Cambridge CB2 0RE, England; | University of Cambridge, CRUK Cambridge Institute, Li Ka Shing Centre, Robinson ...

Richard James Gilbertson: Expert Impact

Concepts for which Richard James Gilbertson has direct influence: Brain tumors , Stem cells , Primary cilia , Brain tumor , Molecular subgroups , Supratentorial ependymoma , Pediatric phase .

Richard James Gilbertson: KOL impact

Concepts related to the work of other authors for which for which Richard James Gilbertson has influence: Stem cells , Brain tumors , Gene expression , Central nervous , Primary cilia , Cell proliferation , Breast cancer .

KOL Resume for Richard James Gilbertson

Year
2022

Department of Oncology, Cancer Research UK Cambridge Institute, Cambridge CB2 0RE, England;

University of Cambridge, CRUK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK. Electronic address:

2021

Cancer Research UK Cambridge Centre, CRUK Cambridge Institute, Li Ka Shing Centre, Cambridge CB2 0RE, UK.

Department of Oncology, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK

2020

Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE

2019

Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Cambridge, UK

Department of Oncology, Addenbrooke's Hospital, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge CB2 0QQ, United Kingdom; email: ,

2018

Cancer Research UK Cambridge Institute and Department of Oncology, University of Cambridge, Cambridge, England, United Kingdom.

Department of Oncology, University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus, Cambridge CB2 0XZ, UK

2017

Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN, USA.

Ingo K. Mellinghoff, Memorial Sloan Kettering Cancer Center, New York, NY; and Richard J. Gilbertson, University of Cambridge, Cambridge, United Kingdom.

2016

Departments of Pharmaceutical Sciences (Y.T.P., M.O.J., A.D.D., D.C.T. C.F.S.), Hematology (N.B.), and Developmental Neurobiology (R.J.G.), Preclinical Pharmacokinetic Shared Resource (P.K.V., B.B.F.), St. Jude Children's Research Hospital, Memphis, Tennessee; Merck, Rahway, New Jersey (D.C.T.); and Cambridge Cancer Centre, Cambridge, United Kingdom (R.J.G.).

Cambridge Cancer Centre, Cambridge, UK

2015

St. Jude Children's Research Hospital, Memphis, TN, USA

Giles W. Robinson, Brent A. Orr, Gang Wu, Tong Lin, Ibrahim Qaddoumi, Sue C. Kaste, Michael Rusch, Sariah J. Allen, Arzu Onar-Thomas, Clinton F. Stewart, James M. Boyett, Richard J. Gilbertson, David W. Ellison, and Amar Gajjar, St Jude Children's Research Hospital, Memphis, TN; Sridharan Gururangan and Annick Desjardins, Duke University Medical Center, Durham, NC; Roger J. Packer, Children's National Medical Center, Washington, DC; Stewart Goldman, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL; Michael D. Prados, University of California San Francisco, San Francisco, CA; Murali Chintagumpala, Texas Children's Cancer Center, Houston, TX; Naoko Takebe, National Cancer Institute, Bethesda, MD; Maryam Fouladi, Cincinnati Children's Hospital, Cincinnati, OH; and Tom Curran, Children's Hospital of Philadelphia, Philadelphia, PA.

Department of Oncology, St Jude Children's Research Hospital, Memphis, Tennessee (K.D.W., R.J.G., A.G.); Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, Tennessee (V.M.D., D.C.T., C.F.S); Department of Biostatistics, St Jude Children's Research Hospital, Memphis, Tennessee (A.O.-T.); Department of Developmental Neurobiology, St Jude Children's Research Hospital, Memphis, Tennessee (N.B., R.J.G.); Department of Pathology, St Jude Children's Research Hospital, Memphis, Tennessee (B.A.O.)

CR UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Robinson Way, Cambridge, CB2 ORE, UK.

2014

Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas (L.B.K., M.C., J.S., S.M.B.); Department of Biostatistics, Operations and Biostatistics Center for Pediatric Brain Tumor Consortium, St. Jude Children's Research Hospital, Memphis, Tennessee (M.K., J.M.B.); Eli Lilly and Company, Indianapolis, Indiana (R.L.D.); Division of Neuro-oncology, St. Jude Children's Research Hospital, Memphis, Tennessee (C.W., R.G.); Ann and Robert H. Lurie Children's Hospital of Chicago, Center for Cancer and Blood Disorders, Northwestern University Feinberg School of Medicine, Chicago, Illinois (S.G.); Department of Pediatrics, Division of Hematology/Oncology, University of California San Francisco, San Francisco, California (A.B.); Department of Hematology Oncology, Cincinnati Children's Hospital Medical Center,Cincinnati, Ohio (M.F.); Department of Radiological Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee (L.K.); Department of Preventive Medicine, University of Tennessee Health Science Center Memphis, Tennessee (M.K.)

St Jude Children’s Research Hospital - Washington University Pediatric Cancer Genome Project, USA

2013

St. Jude Children's Research Hospital, Memphis, Tennessee 03105,

Saint Jude Children's Research Hospital Department of Developmental Neurobiology Memphis, Tennessee

2012

St Jude Children’s Research Hospital - Washington University Pediatric Cancer Genome Project

2011

St Jude Children's Research Hospital, Memphis, TN

Prominent publications by Richard James Gilbertson

KOL-Index: 18217 . BACKGROUND: Medulloblastoma is associated with rare hereditary cancer predisposition syndromes; however, consensus medulloblastoma predisposition genes have not been defined and screening guidelines for genetic counselling and testing for paediatric patients are not available. We aimed to assess and define these genes to provide evidence for future screening guidelines. METHODS: In this ...
Known for Genetic Predisposition | Patients Medulloblastoma | Germline Mutations | Brca2 Palb2
KOL-Index: 16751 . Medulloblastoma is heterogeneous, being characterized by molecular subgroups that demonstrate distinct gene expression profiles. Activation of the WNT or SHH signaling pathway characterizes two of these molecular subgroups, the former associated with low-risk disease and the latter potentially targeted by novel SHH pathway inhibitors. This manuscript reports the validation of a novel ...
Known for Molecular Subgroups | Wnt Shh | Proteins Signal | Immunohistochemical Markers
KOL-Index: 15221 . BACKGROUND: Young children with medulloblastoma have a poor overall survival compared with older children, due to use of radiation-sparing therapy in young children. Radiotherapy is omitted or reduced in these young patients to spare them from debilitating long-term side-effects. We aimed to estimate event-free survival and define the molecular characteristics associated with ...
Known for Young Children | Chemotherapy Patients | Adapted Therapy | Adjuvant Child
KOL-Index: 14007 . PURPOSE: To describe clinical features, therapeutic approaches, and prognostic factors in pediatric patients with atypical teratoid/rhabdoid tumors (ATRT) treated at St Jude Children's Research Hospital (SJCRH). PATIENTS AND METHODS: Primary tumor samples from patients diagnosed with ATRT at SJCRH between July 1984 and June 2003 were identified. Pathology review included histologic, ...
Known for Atrt Patients | Radiation Therapy | Children 3 | Situ Hybridization
KOL-Index: 13752 . Cancer stem cells are remarkably similar to normal stem cells: both self-renew, are multipotent and express common surface markers, for example, prominin 1 (PROM1, also called CD133). What remains unclear is whether cancer stem cells are the direct progeny of mutated stem cells or more mature cells that reacquire stem cell properties during tumour formation. Answering this question will ...
Known for Stem Cells | Neoplastic Transformation | Small Intestinal | Tumour Formation
KOL-Index: 12817 . BACKGROUND: Current treatment for medulloblastoma, which includes postoperative radiotherapy and 1 year of chemotherapy, does not cure many children with high-risk disease. We aimed to investigate the effectiveness of risk-adapted radiotherapy followed by a shortened period of dose-intense chemotherapy in children with medulloblastoma. METHODS: After resection, patients were classified as ...
Known for Dose Chemotherapy | Medulloblastoma Patients | Risk Disease | Craniospinal Radiotherapy
KOL-Index: 12389 . As a single agent the ERBB1 inhibitor, gefitinib (Iressa; ZD1839) showed minimal activity against a panel of 10 pediatric tumor xenografts that do not express the ERBB1 receptor. However, combined with irinotecan (CPT-11), significantly greater than additive activity was observed in four of eight models (P < 0.05), and the combination showed enhanced activity against three additional tumor ...
Known for Oral Bioavailability | Antitumor Activity | Irinotecan Abcg2 | Gefitinib Enhances
KOL-Index: 12232 . The cellular stress response has a vital role in regulating homeostasis by modulating cell survival and death. Stress granules are cytoplasmic compartments that enable cells to survive various stressors. Defects in the assembly and disassembly of stress granules are linked to neurodegenerative diseases, aberrant antiviral responses and cancer1–5. Inflammasomes are multi-protein heteromeric ...
Known for Stress Granules | Activation Inflammasomes | Cell Fate | Ddx3x Nlrp3
KOL-Index: 12155 . PURPOSE: A phase II study of bevacizumab (BVZ) plus irinotecan (CPT-11) was conducted in children with recurrent malignant glioma (MG) and intrinsic brainstem glioma (BSG). PATIENTS AND METHODS: Eligible patients received two doses of BVZ intravenously (10 mg/kg) 2 weeks apart and then BVZ plus CPT-11 every 2 weeks until progressive disease, unacceptable toxicity, or a maximum of 2 years ...
Known for Monoclonal Antibodies | Brainstem Glioma | Bvz Cpt11 | Bevacizumab Irinotecan
KOL-Index: 11914 . Emerging evidence suggests that neural stem cells and brain tumors regulate their proliferation via similar pathways. In a previous study, we demonstrated that maternal embryonic leucine zipper kinase (Melk) is highly expressed in murine neural stem cells and regulates their proliferation. Here we describe how MELK expression is correlated with pathologic grade of brain tumors, and its ...
Known for Stem Cells | Brain Tumors | Melk Proliferation | Key Regulator
KOL-Index: 11362 . Medulloblastoma is the most common malignant brain tumor in childhood. Molecular studies from several groups around the world demonstrated that medulloblastoma is not one disease but comprises a collection of distinct molecular subgroups. However, all these studies reported on different numbers of subgroups. The current consensus is that there are only four core subgroups, which should be ...
Known for 4 Medulloblastomas | Molecular Subgroups | Clinical Data | Genetic Aberrations
KOL-Index: 11054 . PURPOSE: To determine whether preradiotherapy (RT) chemotherapy would improve outcome for Chang stage M0-1 medulloblastoma when compared with RT alone. Chemotherapy comprised vincristine 1.5 mg/m2 weekly for 10 weeks and four cycles of etoposide 100 mg/m2 daily for 3 days, and carboplatin 500 mg/m2 daily for 2 days alternating with cyclophosphamide 1.5 g/m2. PATIENTS AND METHODS: Patients ...
Known for Efs Chemotherapy | International Society | Nonmetastatic Medulloblastoma | 3 Years

Key People For Brain Tumors

Top KOLs in the world
#1
David N Louis
allelic loss central nervous situ hybridization
#2
Peter C Burger
central nervous glioblastoma multiforme brain tumors
#3
Mitchel Stuart Berger
brain tumors surgical resection magnetic resonance
#4
Paul Kleihues
p53 mutations secondary glioblastomas dna methylation
#5
Darell D D Bigner
monoclonal antibodies brain tumors cell lines
#6
Michael Weller
glioma cells newly diagnosed glioblastoma multiple sclerosis

Department of Oncology, Cancer Research UK Cambridge Institute, Cambridge CB2 0RE, England; | University of Cambridge, CRUK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK. Electronic address: richard.gilbertson@cruk.cam